Charming Medical Ltd (MCTA) SEC Filings & Earnings Calls
EquiReason read 12 Charming Medical Ltd SEC filings in the last 12 months. Latest: 6-K on 2026-09-29 — Filing is a proxy statement for an extraordinary general meeting to cancel unissued Class B shares and remove dual-class structure; no material financial or operational event..
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 504.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- —
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
30 Jul 202620-FCharming Medical filed its annual report for FY2026, reporting a net loss of US$22,648, improved liquidity from IPO proceeds, and ongoing trading suspension.earningsopen
Figures in the filing · each found in the filing text
| Working Capital Surplus · FY2026 | $4M | |
| Cash and Cash Equivalents · FY2026 | $5M | |
| Net Loss · FY2026 | $22648.00 | |
| Franchised Stores · FY2026 | 3 | +200% y/y |
| Class A Ordinary Shares Outstanding · FY2026 | 15,178,000 | |
| IPO Gross Proceeds · FY2026 | $7M |
Risks flagged
Trading Suspension and Potential Delisting
“trading in our Class A Ordinary Shares has been suspended or halted since November 12, 2025” · word for word
Securities Class Action Lawsuit
“In December 2025, a securities class action complaint was filed ... alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934” · word for word
Going Concern Risk (Historical)
“Our audited financial statements for the fiscal years ended March 31, 2025 and 2024 contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern” · word for word
Net Loss
“For the fiscal year ended March 31, 2026, we incurred a net loss of US$22,648” · word for word
PRC Regulatory Uncertainty
“the PRC government may exercise significant direct oversight and discretion over the conduct of our business and may intervene or influence our operations” · word for word
21 Jul 20266-KVoluntary adoption of corporate governance enhancements including lock-up agreement, election to follow Nasdaq domestic rules, and abolition of dual-class share structure.open
Figures in the filing · each found in the filing text
| Class B Ordinary Shares surrendered · 2026-07-20 | 2,000,000 | |
| Ordinary Shares outstanding after surrender · 2026-07-20 | 15,178,000 | |
| Voting power of Ms. Wong after surrender · 2026-07-20 | 68.2% |
Risks flagged
No assurance of trading resumption or continued Nasdaq listing; ongoing cooperation with Nasdaq and SEC.
“There can be no assurance, however, as to when or whether trading in its ordinary shares will resume, or that the Company will be able to maintain its listing on Nasdaq.” · word for word
31 Mar 20266-KUnaudited interim results for six months ended Sep 30, 2025: total revenues $2.16M (down 27% YoY), net loss $72,978 vs net income $468,817 prior year; operating loss $94,387 vs income $554,849.earningsopen
Figures in the filing · each found in the filing text
| Total revenues · H1-FY2026 | $2M | -27% y/y |
| Net (loss) income · H1-FY2026 | $-72978.00 | -116% y/y |
| Beauty, wellness and postpartum services revenue · Beauty, wellness and postpartum services · H1-FY2026 | $2M | -31% y/y |
| Cash and cash equivalents · Sep 30, 2025 | $2M |
Risks flagged
Revenue decline and operating loss indicate demand weakness; cash burn may require additional financing.
“Revenue down 27% YoY; operating loss $(94,387) vs prior profit $554,849; net loss $(72,978).”
27 Mar 20266-KIndependent director Josephine Yan Yeung resigned effective March 27, 2026, to pursue other business commitments; no disagreement with company. Board accepted resignation and expects to fill vacancy by April 2, 2026.open
Risks flagged
Loss of independent director; temporary governance gap until replacement is found.
“The Company is in the process of identifying a suitable replacement and expects to fill the vacancy by April 2, 2026.” · word for word
6 Jan 20266-KDirector resignation and appointment of new independent director Yin Jiang with annual compensation of HK$240,000; no disagreement cited.open
Risks flagged
No material risk signals; routine board change.
28 Nov 20256-KNasdaq halted trading pending additional info after SEC suspension; trading halt and SEC suspension indicate high delisting risk.open
Risks flagged
Regulatory and exchange actions (SEC suspension, Nasdaq halt) create material uncertainty about continued listing and investor confidence.
“SEC suspension order and Nasdaq trading halt; company must satisfy Nasdaq's information request.”
13 Nov 20256-KSEC suspended trading in Charming Medical Ltd securities from Nov 12-25, 2025 due to potential social media manipulation; Nasdaq also requested information.open
Risks flagged
SEC trading suspension due to potential social media manipulation; Nasdaq information request; risk of further regulatory action or delisting.
“SEC order suspending trading from Nov 12-25, 2025; Nasdaq information request on Nov 12, 2025.”
Company denies involvement but may face reputational damage and loss of investor trust.
“Company states it has not authorized, participated in, or been involved with any promotion or recommendation of its securities via social media.”
28 Oct 20256-KOver-allotment option exercised in full for 240,000 shares at $4.00, raising $0.96M; total IPO proceeds ~$7.36M. Routine capital event for a newly public company.open
Figures in the filing · each found in the filing text
| Gross proceeds from over-allotment · Q4-2025 | $960000.00 | |
| Total gross proceeds from IPO · Q4-2025 | $7M |
Risks flagged
No material risk signals; routine capital event for a newly public company.
Charming Medical Ltd — questions
- What did Charming Medical Ltd file recently?
- 12 SEC filings in the last 12 months. Latest: 6-K on 2026-09-29 — Filing is a proxy statement for an extraordinary general meeting to cancel unissued Class B shares and remove dual-class structure; no material financial or operational event.
Every figure on this page comes from Charming Medical Ltd's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.